New insights into the management of bleeding disorders.
The Novo Nordisk European Symposium on New Insights into the Management of Bleeding Disorders was held April 23-24, 2004, in Madrid, Spain. More than 200 specialists in the management of congenital and acquired bleeding disorders attended the different sessions. During the symposium, new medical indications for the use of human recombinant activated factor VII (rFVIIa, eptacog alfa activated) were presented. Rationale for new clinical trials and updates on registry for emerging indications were also discussed.
Escolar
Gines
G
Servicio de Hemoterapia y Hemostasia, CDB, Hospital Clinic, Barcelona, Spain. escolar@medicina.ub.es
D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000517:prevention & control; D002986:Clinical Trials as Topic; D005168:Factor VII Deficiency / Q000188:drug therapy; D015942:Factor VIIa / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy; D006470:Hemorrhage / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D013915:Thrombasthenia / Q000188:drug therapy
D011994:Recombinant Proteins; D015942:Factor VIIa